News And Updates

FDA Advisory Panel Backs Broader Access to Compounded Peptides: What Providers and Pharmacies Should Know

FDA PCAC panel votes to advance BPC-157, KPV, TB-500, and MOTS-C toward Section 503A compounding. Learn what this means for providers and pharmacies.

Return to Top

The regulatory landscape for compounded peptides may be poised for a significant shift.

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee ("PCAC") voted in favor of allowing four widely discussed peptides—BPC-157, KPV, TB-500, and MOTS-C—to move forward toward potential inclusion on the list of bulk drug substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The votes are particularly notable because the Committee reached its recommendations despite concerns raised by FDA scientists regarding the limited clinical evidence and potential safety risks associated with the substances. The development could have significant implications for compounding pharmacies, telehealth platforms, medical practices, wellness providers, and other businesses operating in the rapidly expanding peptide market.

The Committee’s votes do not mean that these peptides are now FDA-approved drugs. Nor do the votes immediately authorize unrestricted compounding, prescribing, marketing, or sale of the products. PCAC is an advisory committee. Its recommendations are nonbinding, and the FDA must determine what regulatory action to take next. Accordingly, a favorable PCAC vote should be understood as an important regulatory development, but not as an FDA finding that a peptide is safe and effective for a particular medical use.

If you need guidance or clarification on this or any other healthcare legal issue, you may reach our experienced healthcare attorneys at MDRXLaw via email at info@mdrxlaw.comor by phone or text at 212.668.0200.

Attorney Advertising. Prior results do not guarantee a similar outcome. This website is for general information only and is not legal advice. Viewing it or contacting the firm does not create an attorney-client relationship, and you should not send confidential information until the firm has confirmed it represents you.

Privacy Policy · Opt out of targeted ads